Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZEGALOGUE vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Terminal elimination half-life is 5-7 hours in healthy adults; in hepatic impairment, half-life may be prolonged up to 12 hours, requiring dose adjustment.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Dasiglucagon is metabolized via proteolytic degradation into smaller peptides and amino acids; CYP enzymes are not involved.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Primarily renal excretion of unchanged drug (approximately 70-80%) and minor hepatic metabolism with biliary/fecal elimination (10-15%).
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Approximately 85% bound to albumin and alpha-1-acid glycoprotein.
Negligible for electrolytes and dextrose (<5%).
0.6-0.8 L/kg, indicating moderate tissue distribution with concentrations in tissues approximately 1.5 times plasma.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Oral: 40-50% (due to first-pass metabolism); Intramuscular: 90-100%.
Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Not recommended for use in patients with end-stage renal disease (e GFR <15 m L/min/1.73 m2) due to lack of data.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended in these patients.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Not indicated for pediatric patients; safety and efficacy in patients <18 years have not been established.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
No specific dose adjustment required based on age alone. However, dosing should be cautious due to potential for decreased renal function or comorbidities; monitor renal function and volume status.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Risk of serious hypersensitivity reactions including anaphylaxis,May cause nausea and vomiting,Risk of hypoglycemia if used in patients with insulinoma or glucagonoma,May increase blood pressure and heart rate
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Pheochromocytoma,Insulinoma,Known hypersensitivity to dasiglucagon or any excipients
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No specific food interactions. After recovery, administer oral carbohydrates to replenish liver glycogen and prevent recurrent hypoglycemia. Avoid alcohol as it may impair glucose recovery.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk cannot be excluded; use only if benefit outweighs risk. Fetal risks: potential for maternal hypoglycemia-induced fetal distress if not treated.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
No data on presence in human milk; dasiglucagon is a peptide likely degraded in GI tract. M/P ratio not determined. Caution in breastfeeding; consider risk of infant exposure vs benefit of treating maternal hypoglycemia.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No pharmacokinetic data in pregnancy; dosing adjustments not recommended. Use standard dose (0.6 mg) for severe hypoglycemia regardless of trimester.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
ZEGALOGUE (dasiglucagon) is a soluble glucagon analog indicated for severe hypoglycemia. It is stable in liquid form, avoiding reconstitution. Onset of action is 10-15 minutes, with blood glucose rise similar to native glucagon. Note that it can cause nausea and vomiting; if patient is unconscious, place in recovery position. Do not use if patient has pheochromocytoma, insulinoma, or known hypersensitivity. Store at room temperature.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
Use only for severe hypoglycemia when patient is unable to take carbs orally or is unconscious.,Inject into buttock, thigh, or abdomen; no need to mix or reconstitute.,After injection, call emergency services immediately.,Administer supplemental carbs (if conscious and can swallow) after blood glucose responds.,Common side effects: nausea, vomiting, headache, injection site pain.,Store at controlled room temperature (20-25°C); do not freeze.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZEGALOGUE vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ZEGALOGUE is a GnRH Antagonist that works by ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZEGALOGUE and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZEGALOGUE is: Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZEGALOGUE and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZEGALOGUE is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk c. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.